Lehrstuhl für Geburtshilfe und Frauenheilkunde

Optimization of Porcine Ovarian Follicle Isolation Methods for Better Developmental Potential (2020) Fattahi A, Liverani L, Dittrich R, Hoffmann I, Boccaccini AR, Beckmann M, Bleisinger N Journal article Development and validation of the gene-expression Predictor of high-grade-serous Ovarian carcinoma molecular subTYPE (PrOTYPE) (2020) Talhouk A, George J, Wang C, Budden T, Tan TZ, Chiu DS, Kommoss S, et al. Journal article Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk (2020) Liu J, Prager-van der Smissen WJ, Collée JM, Bolla MK, Wang Q, Michailidou K, Dennis J, et al. Journal article Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor α (2020) Ingle JN, Cairns J, Suman VJ, Shepherd LE, Fasching P, Hoskin TL, Singh RJ, et al. Journal article ABC5 International Consensus Conference on Advanced Breast Cancer, Lisbon, 16 November 2019 (2020) Untch M, Würstlein R, Lüftner D, Haidinger R, Fasching P, Augustin D, Briest S, et al. Journal article, Review article Tumor handling of early-stage cervical cancer: A literature analysis of villoglandular adenocarcinoma of the cervix (2020) Dietl A, Aumann K, Beckmann M Journal article, Review article Logbooks alone are not enough: initial experience with implementing a logbook for medical students in a clinical internship in gynecology and obstetrics (2020) Jud S, Cupisti S, Frobenius W, Benn S, Winkler A, Antoniadis S, Beckmann M, Heindl F Journal article Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib (RIB) plus fulvestrant (FUL) as first-line (1L) and second-line (2L) therapy in MONALEESA-3 (ML-3) (2020) Fasching P, Neven P, Jerusalem G, Beck JT, Chan A, De Laurentiis M, Bianchi GV, et al. Conference contribution Predicting prognosis of breast cancer patients with brain metastases in the BMBC registry: Comparison of three different (2020) Riecke K, Mueller V, Neunhoeffer T, Weide R, Schmidt M, Park-Simon TW, Mundhenke C, et al. Conference contribution Quality-adjusted survival with ribociclib plus fulvestrant (R plus F) versus placebo plus fulvestrant (P plus F) in postmenopausal women (PMW) HR+/HER2-advanced breast cancer (ABC) based on the MONALEESA-3 trial (2020) Jerusalem G, Delea T, Martin Jimenez M, De Laurentiis M, Nusch A, Beck JT, Chan A, et al. Conference contribution